U.S. pharma giant copyright scrapped two experimental weight loss capsules very last calendar year—a once-day-to-day capsule, lotiglipron, because of elevated liver enzymes as well as a twice-everyday tablet, danuglipron, because of sturdy Unintended effects—but CEO Albert Bourla has explained the company is determined to “play and acquire”